Hypofractionated Radiotherapy for Prostate Cancer (62 Gy in 20 Fractions of 3.1 Gy) With Hyaluronic Acid Injection
The Phase II trial sponsored by Hospices Civils de Lyon investigates the efficacy of hyaluronic acid (HA) as a spacer to mitigate late rectal toxicities in patients undergoing hypofractionated radiotherapy for prostate cancer. With a focus on low- to intermediate-risk patients, this study could potentially enhance treatment tolerability and patient outcomes, thereby positioning HA as a valuable adjunct in prostate cancer radiotherapy. The reduction in treatment duration from 40 to 20 fractions may also appeal to healthcare providers seeking efficiency in treatment protocols. If successful, this could lead to broader adoption of HA in clinical practice, impacting market dynamics in the oncology space, particularly in radiotherapy adjuncts. Competitive analysis should consider existing spacer technologies and their market penetration, as well as the regulatory landscape for medical devices in oncology.
Indication: Prostate Cancer
Modality: medical device
Target: Hyaluronic acid injection in the perirectal fat to reduce late rectal toxicities during hypofractionated radiotherapy for prostate cancer.
Sponsor: Hospices Civils de Lyon
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 14, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Hyaluronic acid injection in the perirectal fat to reduce late rectal toxicities during hypofractionated radiotherapy for prostate cancer.
View original source fields
Condition raw: Prostate Cancer
Condition normalized: Prostate Cancer
Modality raw: medical device
Modality normalized: medical device
Target raw: Hyaluronic acid injection in the perirectal fat to reduce late rectal toxicities during hypofractionated radiotherapy for prostate cancer.
Target normalized: Hyaluronic acid injection in the perirectal fat to reduce late rectal toxicities during hypofractionated radiotherapy for prostate cancer.